Popular Articles

Daily Women's Health Policy Report Summarizes Studies Examining Ovarian Cancer
The following summarizes recent research related to ovarian cancer.~ Early periods linked to lower survival: Women who start menstruating at an early age or experience more menstrual cycles over their lifetimes appear to have a lower chance of surviving ovarian cancer, according to a study published this month in the journal Cancer Epidemiology, Biomarkers, and Prevention, Reuters reports. For the study, researcher Cheryl Robbins and colleagues analyzed the medical data of 410 ovarian cancer patients who participated in the Cancer and Steroid Hormone study between 1980 and 1982. The analysis found that the women who had their first period before age 12 had a 51% greater risk of dying than the women who began menstruating at age 14 or older. The women who had the highest number of lifetime menstrual cycles had a 67% greater risk of dying during follow-up than the women with the lowest number of cycles (Reuters, 7/24).~ Lung cancer risk higher for women after hysterectomy with ovary removal: Women who have had hysterectomies in which their uterus and both ovaries are removed to prevent ovarian cancer appear to have a higher risk for developing lung cancer, according to researchers at the University of Montreal, the New York Times reports. The researchers discovered the connection while looking for links between lung cancer and hormones for a study published in May in the International Journal of Cancer. Although they did not find a relationship between lung cancer risk and hormonal factors such as menstruation patterns, child-bearing or breastfeeding, the researchers found that women who had medically induced menopause had 1.92 times greater risk of developing lung cancer than women who had natural menopause (Caryn Rabin, New York Times, 7/24).~ Small tumors present for years before detection: Minute-sized ovarian tumors form and remain in the Fallopian tubes for an average of four years before they grow large enough to be detected, which might suggest why ovarian cancer frequently is diagnosed in its later stages, according to a study published in the journal PLoS Medicine, Reuters reports. For the study, lead researcher Patrick Brown of Stanford University and the Howard Hughes Medical Institute and colleagues analyzed the tumors of women whose Fallopian tubes and ovaries were removed because they had family histories of and genetic risk for ovarian cancer. They found small tumors -- most less than three millimeters in diameter -- that previously had not been detected in the women. In a statement, Brown said, "There is a long window of opportunity for potentially lifesaving early detection of this disease, but the tumor spreads while it is still much too small to be detected by any of the tests that have been developed or proposed to date." According to Reuters, blood tests for the compound called CA-125 may help guide therapy but do not indicate whether a woman has a tumor (Reuters, 7/28).

Editorials And Opinions
A Selection of Editorials and Opinions
News of the day
Gene Discovery Suggests Cancer Drugs Might Treat Alcoholism
A class of drugs already approved as cancer treatments might also help to beat alcohol addiction. That"s the conclusion of a discovery in flies of a gene, dubbed happyhour, that has an important and previously unknown role in controlling the insects" response to alcohol.
Public Health

Cytori Reports Publication Of Cardiovascular Preclinical Study; Adipose Stem & Regenerative Cells Improve Function In Heart Attack Model

Cytori (NASDAQ: CYTX) announced publication of the first preclinical study to demonstrate adipose-derived stem and regenerative cells (ADRCs) significantly improved cardiac function after a heart attack. This preclinical cardiac cell therapy study was reported online ahead of print in the International Journal of Cardiology. The study was funded by Cytori Therapeutics and conducted at Tulane University. "Treatment of cardiovascular disease, which places one of the greatest burdens on our healthcare system, could be revolutionized by cell therapy," said Marc H. Hedrick, M.D., president of Cytori. "We observed a statistically significant improvement in heart function that contributed to our decision to proceed with our APOLLO study. Cardiovascular disease is the most advanced application in Cytori"s product pipeline and could eventually make a substantial contribution to our future commercial activities." The APOLLO study is the first clinical trial to investigate uncultured adipose-derived stem and regenerative cells in heart attacks in human patients. Enrollment was recently completed in APOLLO, a double blind, placebo controlled, safety and feasibility trial. Data are expected to be reported in early 2010. The APOLLO study is sponsored by Cytori and has incorporated the Company"s Celution® System to automate the processing of the patients" cells at the point of care. In Cytori"s preclinical study, 17 large animals (pigs) were treated with their own uncultured adipose-derived stem and regenerative cells immediately following induction of a severe myocardial infarction. Uncultured cells include a multitude of heterogeneous cell types that Cytori believes facilitate several therapeutic mechanisms. Several functional measurements within the study indicated statistically significant improvement in both heart function and structure. Cytori


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):